 Stephen Waldo
Concepts (415)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Percutaneous Coronary Intervention | 77 | 2025 | 480 | 19.320 |
Why?
| | Coronary Artery Disease | 45 | 2025 | 698 | 10.920 |
Why?
| | United States Department of Veterans Affairs | 32 | 2025 | 678 | 5.780 |
Why?
| | Coronary Angiography | 31 | 2025 | 317 | 3.690 |
Why?
| | Myocardial Infarction | 29 | 2025 | 1046 | 3.390 |
Why?
| | Peripheral Arterial Disease | 25 | 2020 | 475 | 3.360 |
Why?
| | Endovascular Procedures | 18 | 2020 | 312 | 3.250 |
Why?
| | Femoral Artery | 13 | 2022 | 179 | 2.800 |
Why?
| | Acute Coronary Syndrome | 8 | 2025 | 279 | 2.770 |
Why?
| | Treatment Outcome | 91 | 2025 | 10811 | 2.760 |
Why?
| | Veterans | 18 | 2025 | 1476 | 2.760 |
Why?
| | Vascular Calcification | 9 | 2022 | 108 | 2.430 |
Why?
| | Veterans Health | 7 | 2025 | 186 | 2.340 |
Why?
| | Stents | 21 | 2019 | 527 | 2.300 |
Why?
| | ST Elevation Myocardial Infarction | 6 | 2022 | 54 | 2.200 |
Why?
| | Popliteal Artery | 11 | 2020 | 59 | 2.180 |
Why?
| | Registries | 28 | 2023 | 2035 | 2.030 |
Why?
| | Coronary Artery Bypass | 8 | 2025 | 234 | 2.000 |
Why?
| | Atherectomy | 11 | 2022 | 37 | 2.000 |
Why?
| | Risk Factors | 70 | 2025 | 10388 | 1.990 |
Why?
| | Ischemia | 11 | 2020 | 409 | 1.820 |
Why?
| | United States | 62 | 2025 | 14841 | 1.790 |
Why?
| | Time Factors | 52 | 2025 | 6828 | 1.780 |
Why?
| | Atherectomy, Coronary | 5 | 2022 | 10 | 1.750 |
Why?
| | Aged | 88 | 2025 | 23961 | 1.740 |
Why?
| | Risk Assessment | 29 | 2025 | 3457 | 1.710 |
Why?
| | Platelet Aggregation Inhibitors | 8 | 2025 | 463 | 1.640 |
Why?
| | Time-to-Treatment | 5 | 2024 | 205 | 1.600 |
Why?
| | Radial Artery | 7 | 2022 | 68 | 1.600 |
Why?
| | Lower Extremity | 4 | 2018 | 427 | 1.580 |
Why?
| | Angioplasty, Balloon, Coronary | 6 | 2017 | 141 | 1.570 |
Why?
| | Middle Aged | 82 | 2025 | 33479 | 1.460 |
Why?
| | Hospitals, Veterans | 5 | 2025 | 252 | 1.420 |
Why?
| | Cardiovascular Agents | 7 | 2023 | 159 | 1.360 |
Why?
| | Humans | 158 | 2025 | 137585 | 1.360 |
Why?
| | Non-ST Elevated Myocardial Infarction | 3 | 2020 | 22 | 1.320 |
Why?
| | Hospital Mortality | 13 | 2025 | 911 | 1.290 |
Why?
| | Biological Products | 2 | 2023 | 216 | 1.290 |
Why?
| | Male | 101 | 2025 | 67762 | 1.230 |
Why?
| | Coronary Restenosis | 4 | 2017 | 21 | 1.210 |
Why?
| | Coronary Vessels | 7 | 2025 | 248 | 1.210 |
Why?
| | Angioplasty, Balloon | 9 | 2020 | 93 | 1.190 |
Why?
| | Myocardial Ischemia | 5 | 2025 | 263 | 1.160 |
Why?
| | Female | 95 | 2025 | 73304 | 1.110 |
Why?
| | Myocardial Revascularization | 3 | 2019 | 73 | 1.100 |
Why?
| | Retrospective Studies | 53 | 2025 | 15657 | 1.090 |
Why?
| | Access to Information | 2 | 2019 | 49 | 1.080 |
Why?
| | Catheterization, Peripheral | 2 | 2019 | 109 | 1.060 |
Why?
| | Surgical Procedures, Operative | 3 | 2025 | 259 | 0.970 |
Why?
| | Angina, Stable | 3 | 2022 | 17 | 0.940 |
Why?
| | Patient Readmission | 9 | 2025 | 697 | 0.940 |
Why?
| | Eligibility Determination | 1 | 2025 | 65 | 0.900 |
Why?
| | Coated Materials, Biocompatible | 6 | 2020 | 62 | 0.890 |
Why?
| | Cardiology | 4 | 2022 | 274 | 0.880 |
Why?
| | Quality Improvement | 5 | 2025 | 1178 | 0.880 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2025 | 261 | 0.880 |
Why?
| | Quality of Health Care | 3 | 2025 | 642 | 0.850 |
Why?
| | Myocardial Reperfusion | 2 | 2013 | 50 | 0.840 |
Why?
| | Community Health Services | 1 | 2025 | 227 | 0.830 |
Why?
| | Cardiac Catheterization | 5 | 2025 | 530 | 0.830 |
Why?
| | Stroke Volume | 3 | 2021 | 612 | 0.800 |
Why?
| | Vascular Patency | 14 | 2020 | 106 | 0.800 |
Why?
| | Ventricular Function, Left | 3 | 2021 | 534 | 0.790 |
Why?
| | Chickens | 1 | 2023 | 191 | 0.780 |
Why?
| | Heart Arrest | 3 | 2017 | 339 | 0.770 |
Why?
| | Vascular Access Devices | 5 | 2020 | 26 | 0.760 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 179 | 0.760 |
Why?
| | Coronary Thrombosis | 4 | 2015 | 25 | 0.750 |
Why?
| | Psoriasis | 1 | 2023 | 102 | 0.750 |
Why?
| | Healthcare Disparities | 3 | 2024 | 654 | 0.740 |
Why?
| | California | 18 | 2019 | 431 | 0.730 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2023 | 445 | 0.720 |
Why?
| | Aged, 80 and over | 23 | 2025 | 7635 | 0.720 |
Why?
| | Practice Patterns, Physicians' | 7 | 2025 | 1313 | 0.720 |
Why?
| | Anemia | 2 | 2022 | 170 | 0.710 |
Why?
| | Coronary Occlusion | 2 | 2023 | 19 | 0.700 |
Why?
| | Patient Selection | 1 | 2025 | 696 | 0.700 |
Why?
| | Heart Failure, Systolic | 1 | 2021 | 25 | 0.700 |
Why?
| | Hemorrhage | 5 | 2022 | 722 | 0.670 |
Why?
| | Hospitals, Community | 1 | 2020 | 52 | 0.660 |
Why?
| | Drug-Eluting Stents | 6 | 2017 | 81 | 0.660 |
Why?
| | Paclitaxel | 2 | 2019 | 230 | 0.640 |
Why?
| | Assisted Circulation | 1 | 2019 | 26 | 0.640 |
Why?
| | Hemostatic Techniques | 1 | 2020 | 46 | 0.630 |
Why?
| | Cardiovascular Diseases | 4 | 2025 | 2111 | 0.620 |
Why?
| | Quality Indicators, Health Care | 4 | 2025 | 307 | 0.620 |
Why?
| | Embolic Protection Devices | 1 | 2019 | 12 | 0.610 |
Why?
| | Postoperative Complications | 5 | 2025 | 2654 | 0.610 |
Why?
| | Postoperative Hemorrhage | 1 | 2020 | 86 | 0.610 |
Why?
| | Saphenous Vein | 1 | 2019 | 35 | 0.610 |
Why?
| | Intra-Aortic Balloon Pumping | 1 | 2019 | 18 | 0.610 |
Why?
| | Graft Occlusion, Vascular | 1 | 2019 | 40 | 0.610 |
Why?
| | Cardiac Surgical Procedures | 2 | 2022 | 530 | 0.610 |
Why?
| | Databases, Factual | 11 | 2025 | 1357 | 0.600 |
Why?
| | Fibrinolytic Agents | 2 | 2018 | 270 | 0.590 |
Why?
| | Electrocardiography | 4 | 2015 | 629 | 0.590 |
Why?
| | Arterial Occlusive Diseases | 1 | 2018 | 83 | 0.560 |
Why?
| | Arm | 1 | 2018 | 104 | 0.560 |
Why?
| | Peripheral Vascular Diseases | 1 | 2018 | 103 | 0.550 |
Why?
| | Odds Ratio | 8 | 2021 | 1070 | 0.550 |
Why?
| | Thromboembolism | 1 | 2018 | 119 | 0.550 |
Why?
| | Propensity Score | 6 | 2024 | 294 | 0.540 |
Why?
| | Kaplan-Meier Estimate | 12 | 2020 | 889 | 0.540 |
Why?
| | Cerebrovascular Disorders | 1 | 2018 | 96 | 0.540 |
Why?
| | Limb Salvage | 7 | 2019 | 57 | 0.540 |
Why?
| | Embolism | 1 | 2017 | 41 | 0.520 |
Why?
| | Renal Artery Obstruction | 1 | 2017 | 30 | 0.520 |
Why?
| | Renal Artery | 1 | 2017 | 37 | 0.520 |
Why?
| | Aspirin | 2 | 2019 | 387 | 0.520 |
Why?
| | Contrast Media | 4 | 2025 | 467 | 0.510 |
Why?
| | Heart Failure | 6 | 2023 | 2236 | 0.510 |
Why?
| | Research Report | 1 | 2017 | 83 | 0.510 |
Why?
| | Hospitals | 4 | 2023 | 691 | 0.500 |
Why?
| | Transcatheter Aortic Valve Replacement | 3 | 2025 | 130 | 0.500 |
Why?
| | Catheterization | 3 | 2021 | 179 | 0.490 |
Why?
| | Coronary Stenosis | 5 | 2020 | 38 | 0.470 |
Why?
| | Hospitalization | 4 | 2025 | 2199 | 0.460 |
Why?
| | Iliac Artery | 4 | 2019 | 55 | 0.460 |
Why?
| | Hypertension, Pulmonary | 5 | 2025 | 1910 | 0.450 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 220 | 0.440 |
Why?
| | Disclosure | 1 | 2015 | 113 | 0.440 |
Why?
| | Cell Separation | 1 | 2015 | 318 | 0.420 |
Why?
| | Thrombectomy | 2 | 2014 | 69 | 0.420 |
Why?
| | Cohort Studies | 10 | 2023 | 5742 | 0.420 |
Why?
| | Atherosclerosis | 3 | 2019 | 415 | 0.410 |
Why?
| | Depressive Disorder | 1 | 2017 | 379 | 0.410 |
Why?
| | Vascular Surgical Procedures | 1 | 2016 | 303 | 0.410 |
Why?
| | Cardiologists | 2 | 2025 | 45 | 0.400 |
Why?
| | Predictive Value of Tests | 9 | 2025 | 2031 | 0.390 |
Why?
| | Acute Kidney Injury | 5 | 2025 | 815 | 0.390 |
Why?
| | Disease Management | 1 | 2017 | 628 | 0.390 |
Why?
| | Survival Rate | 6 | 2021 | 1972 | 0.390 |
Why?
| | Incidence | 8 | 2025 | 2804 | 0.380 |
Why?
| | Peer Review | 2 | 2025 | 49 | 0.380 |
Why?
| | HIV | 1 | 2013 | 234 | 0.380 |
Why?
| | Logistic Models | 6 | 2017 | 2074 | 0.370 |
Why?
| | Intermittent Claudication | 3 | 2017 | 118 | 0.360 |
Why?
| | Attitude of Health Personnel | 1 | 2019 | 1171 | 0.360 |
Why?
| | Hypothermia | 1 | 2011 | 36 | 0.360 |
Why?
| | Out-of-Hospital Cardiac Arrest | 2 | 2024 | 72 | 0.350 |
Why?
| | Stroke | 7 | 2025 | 1120 | 0.340 |
Why?
| | Cause of Death | 3 | 2023 | 434 | 0.340 |
Why?
| | Severity of Illness Index | 8 | 2025 | 2828 | 0.330 |
Why?
| | Aortic Valve Stenosis | 2 | 2025 | 229 | 0.320 |
Why?
| | Endothelial Cells | 1 | 2015 | 785 | 0.310 |
Why?
| | Proportional Hazards Models | 9 | 2023 | 1266 | 0.310 |
Why?
| | Mentoring | 2 | 2023 | 149 | 0.310 |
Why?
| | Constriction, Pathologic | 9 | 2020 | 245 | 0.310 |
Why?
| | Peptide Fragments | 2 | 2015 | 706 | 0.300 |
Why?
| | Mortality | 3 | 2020 | 362 | 0.300 |
Why?
| | Chi-Square Distribution | 4 | 2018 | 530 | 0.300 |
Why?
| | Punctures | 2 | 2019 | 40 | 0.290 |
Why?
| | Angiography | 6 | 2020 | 207 | 0.290 |
Why?
| | Laser Therapy | 2 | 2019 | 130 | 0.280 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2008 | 99 | 0.280 |
Why?
| | Carotid Stenosis | 2 | 2018 | 91 | 0.270 |
Why?
| | Emergency Medical Services | 1 | 2013 | 552 | 0.260 |
Why?
| | Myocardial Perfusion Imaging | 2 | 2019 | 40 | 0.260 |
Why?
| | Recurrence | 9 | 2019 | 1060 | 0.250 |
Why?
| | HIV Infections | 3 | 2023 | 2836 | 0.250 |
Why?
| | Sex Factors | 5 | 2025 | 2071 | 0.250 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2021 | 382 | 0.250 |
Why?
| | Multivariate Analysis | 5 | 2017 | 1509 | 0.240 |
Why?
| | Ultrasonography, Interventional | 2 | 2025 | 141 | 0.240 |
Why?
| | Macrophages | 3 | 2008 | 1547 | 0.240 |
Why?
| | Acute Disease | 3 | 2017 | 1007 | 0.240 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2023 | 66 | 0.240 |
Why?
| | Patient Discharge | 3 | 2022 | 897 | 0.240 |
Why?
| | Cytochrome P-450 CYP2C19 | 1 | 2025 | 25 | 0.240 |
Why?
| | Peer Review, Health Care | 1 | 2025 | 4 | 0.230 |
Why?
| | Tomography, Optical Coherence | 2 | 2025 | 213 | 0.230 |
Why?
| | Renal Insufficiency, Chronic | 2 | 2023 | 617 | 0.230 |
Why?
| | Chemokine CXCL12 | 1 | 2025 | 81 | 0.230 |
Why?
| | Chest Pain | 3 | 2022 | 91 | 0.230 |
Why?
| | Health Services Accessibility | 2 | 2025 | 986 | 0.220 |
Why?
| | Travel | 1 | 2025 | 130 | 0.220 |
Why?
| | Follow-Up Studies | 6 | 2021 | 5131 | 0.220 |
Why?
| | Comorbidity | 5 | 2020 | 1622 | 0.220 |
Why?
| | Pancreas | 2 | 2004 | 329 | 0.220 |
Why?
| | Prosthesis Failure | 2 | 2016 | 123 | 0.210 |
Why?
| | Hypothermia, Induced | 1 | 2024 | 80 | 0.210 |
Why?
| | Hypertension, Portal | 1 | 2024 | 64 | 0.210 |
Why?
| | Coronary Circulation | 2 | 2014 | 143 | 0.200 |
Why?
| | Heart Valve Prosthesis Implantation | 1 | 2025 | 180 | 0.200 |
Why?
| | Cross-Sectional Studies | 6 | 2022 | 5472 | 0.200 |
Why?
| | Fractional Flow Reserve, Myocardial | 2 | 2020 | 9 | 0.200 |
Why?
| | Biological Therapy | 1 | 2023 | 29 | 0.200 |
Why?
| | New York | 3 | 2017 | 126 | 0.200 |
Why?
| | Prognosis | 6 | 2021 | 4030 | 0.190 |
Why?
| | Work Engagement | 1 | 2022 | 11 | 0.190 |
Why?
| | Clinical Decision-Making | 1 | 2025 | 322 | 0.190 |
Why?
| | Chronic Disease | 5 | 2023 | 1793 | 0.190 |
Why?
| | Leukocytes | 1 | 2003 | 311 | 0.180 |
Why?
| | Technology Transfer | 1 | 2021 | 9 | 0.180 |
Why?
| | Critical Illness | 8 | 2020 | 811 | 0.180 |
Why?
| | Hemodynamics | 4 | 2024 | 1113 | 0.180 |
Why?
| | Social Class | 1 | 2023 | 282 | 0.180 |
Why?
| | Shock, Cardiogenic | 2 | 2021 | 63 | 0.170 |
Why?
| | Anticoagulants | 2 | 2016 | 664 | 0.170 |
Why?
| | Angina Pectoris | 1 | 2020 | 65 | 0.170 |
Why?
| | Aftercare | 1 | 2022 | 208 | 0.170 |
Why?
| | Mandatory Reporting | 2 | 2017 | 45 | 0.170 |
Why?
| | Thrombocytopenia | 1 | 2022 | 200 | 0.160 |
Why?
| | Patient Care Team | 1 | 2025 | 631 | 0.160 |
Why?
| | Exercise Test | 2 | 2022 | 625 | 0.160 |
Why?
| | Massachusetts | 2 | 2017 | 172 | 0.160 |
Why?
| | Referral and Consultation | 1 | 2025 | 786 | 0.160 |
Why?
| | Genome-Wide Association Study | 2 | 2025 | 1431 | 0.150 |
Why?
| | Echocardiography, Stress | 1 | 2019 | 25 | 0.150 |
Why?
| | Health Facilities | 1 | 2019 | 84 | 0.150 |
Why?
| | Intraoperative Period | 1 | 2019 | 59 | 0.150 |
Why?
| | Delivery of Health Care | 2 | 2023 | 951 | 0.150 |
Why?
| | Vascular Resistance | 1 | 2020 | 375 | 0.150 |
Why?
| | Ambulatory Surgical Procedures | 1 | 2019 | 66 | 0.150 |
Why?
| | Fluid Therapy | 1 | 2020 | 147 | 0.150 |
Why?
| | Heart | 1 | 2022 | 655 | 0.150 |
Why?
| | Centralized Hospital Services | 1 | 2018 | 6 | 0.150 |
Why?
| | Socioeconomic Factors | 1 | 2023 | 1289 | 0.150 |
Why?
| | Thrombosis | 1 | 2022 | 371 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2019 | 233 | 0.140 |
Why?
| | Perioperative Care | 1 | 2020 | 178 | 0.140 |
Why?
| | Colorado | 8 | 2019 | 4565 | 0.140 |
Why?
| | Angioplasty, Balloon, Laser-Assisted | 1 | 2017 | 1 | 0.140 |
Why?
| | Perception | 1 | 2021 | 359 | 0.140 |
Why?
| | Transportation of Patients | 1 | 2018 | 55 | 0.140 |
Why?
| | Disease-Free Survival | 5 | 2017 | 686 | 0.140 |
Why?
| | Biomarkers | 4 | 2017 | 4149 | 0.140 |
Why?
| | Angioplasty | 1 | 2018 | 47 | 0.140 |
Why?
| | Pregnancy-Associated Plasma Protein-A | 1 | 2017 | 14 | 0.140 |
Why?
| | Cardiac Catheters | 1 | 2017 | 15 | 0.140 |
Why?
| | Diabetes Mellitus, Type 2 | 2 | 2023 | 2531 | 0.140 |
Why?
| | Rosuvastatin Calcium | 1 | 2017 | 22 | 0.140 |
Why?
| | Algorithms | 2 | 2017 | 1704 | 0.140 |
Why?
| | ADAMTS13 Protein | 1 | 2017 | 7 | 0.140 |
Why?
| | Macrophage Colony-Stimulating Factor | 2 | 2008 | 21 | 0.140 |
Why?
| | Pulmonary Artery | 1 | 2023 | 1086 | 0.140 |
Why?
| | Computer Simulation | 1 | 2021 | 978 | 0.130 |
Why?
| | Neck | 1 | 2017 | 101 | 0.130 |
Why?
| | Thrombotic Microangiopathies | 1 | 2017 | 20 | 0.130 |
Why?
| | Ankle Brachial Index | 1 | 2017 | 37 | 0.130 |
Why?
| | Clinical Competence | 1 | 2025 | 1118 | 0.130 |
Why?
| | Risk | 2 | 2019 | 912 | 0.130 |
Why?
| | Suction | 2 | 2014 | 34 | 0.130 |
Why?
| | Reproducibility of Results | 5 | 2025 | 3284 | 0.130 |
Why?
| | Policy Making | 1 | 2017 | 98 | 0.130 |
Why?
| | Flow Cytometry | 2 | 2015 | 1178 | 0.130 |
Why?
| | Aortic Valve | 1 | 2019 | 351 | 0.130 |
Why?
| | Health Services Needs and Demand | 1 | 2018 | 273 | 0.130 |
Why?
| | Adult | 7 | 2024 | 37929 | 0.120 |
Why?
| | Boston | 1 | 2016 | 91 | 0.120 |
Why?
| | Academic Medical Centers | 2 | 2016 | 512 | 0.120 |
Why?
| | Dyslipidemias | 1 | 2017 | 176 | 0.120 |
Why?
| | Burnout, Professional | 1 | 2022 | 442 | 0.120 |
Why?
| | Pandemics | 2 | 2021 | 1639 | 0.120 |
Why?
| | Cholesterol | 2 | 2008 | 410 | 0.120 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2007 | 220 | 0.110 |
Why?
| | Contraindications | 1 | 2014 | 90 | 0.110 |
Why?
| | Antithrombins | 1 | 2015 | 60 | 0.110 |
Why?
| | Aortic Diseases | 1 | 2016 | 119 | 0.110 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1774 | 0.110 |
Why?
| | Collateral Circulation | 1 | 2014 | 19 | 0.110 |
Why?
| | Models, Cardiovascular | 1 | 2015 | 198 | 0.110 |
Why?
| | Prevalence | 2 | 2019 | 2734 | 0.110 |
Why?
| | Observer Variation | 3 | 2025 | 343 | 0.100 |
Why?
| | Prospective Studies | 3 | 2020 | 7604 | 0.100 |
Why?
| | Heparin | 1 | 2015 | 261 | 0.100 |
Why?
| | Resuscitation | 1 | 2015 | 251 | 0.100 |
Why?
| | Incidental Findings | 1 | 2013 | 87 | 0.100 |
Why?
| | Diabetes Mellitus | 2 | 2018 | 1040 | 0.100 |
Why?
| | Primary Prevention | 1 | 2014 | 196 | 0.100 |
Why?
| | Smoking Cessation | 1 | 2016 | 442 | 0.090 |
Why?
| | Coronary Disease | 1 | 2014 | 385 | 0.090 |
Why?
| | Trazodone | 1 | 2011 | 2 | 0.090 |
Why?
| | Antimanic Agents | 1 | 2011 | 18 | 0.090 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2023 | 82 | 0.090 |
Why?
| | Electronic Health Records | 2 | 2017 | 1069 | 0.090 |
Why?
| | Lithium | 1 | 2011 | 43 | 0.090 |
Why?
| | Triazines | 1 | 2011 | 43 | 0.090 |
Why?
| | Laboratories | 2 | 2022 | 113 | 0.090 |
Why?
| | American Heart Association | 2 | 2022 | 306 | 0.090 |
Why?
| | Prosthesis Design | 3 | 2017 | 327 | 0.080 |
Why?
| | Decision Support Techniques | 1 | 2014 | 421 | 0.080 |
Why?
| | Benzodiazepines | 1 | 2011 | 155 | 0.080 |
Why?
| | Anticonvulsants | 1 | 2011 | 217 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2008 | 1991 | 0.080 |
Why?
| | Age Factors | 4 | 2019 | 3295 | 0.080 |
Why?
| | Lipoproteins, LDL | 2 | 2007 | 116 | 0.080 |
Why?
| | Depression | 1 | 2018 | 1397 | 0.080 |
Why?
| | Bipolar Disorder | 1 | 2011 | 263 | 0.070 |
Why?
| | MicroRNAs | 1 | 2015 | 692 | 0.070 |
Why?
| | Seizures | 1 | 2011 | 426 | 0.070 |
Why?
| | Pinocytosis | 1 | 2007 | 11 | 0.070 |
Why?
| | Area Under Curve | 1 | 2008 | 314 | 0.070 |
Why?
| | Ultrasonography, Doppler, Duplex | 2 | 2017 | 43 | 0.070 |
Why?
| | Animals | 4 | 2025 | 36940 | 0.070 |
Why?
| | Monocytes | 2 | 2007 | 563 | 0.070 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2008 | 152 | 0.070 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 390 | 0.070 |
Why?
| | Drug Overdose | 1 | 2011 | 347 | 0.070 |
Why?
| | Phenotype | 2 | 2021 | 3196 | 0.060 |
Why?
| | ROC Curve | 1 | 2008 | 554 | 0.060 |
Why?
| | Inflammation | 3 | 2008 | 2837 | 0.060 |
Why?
| | Adrenergic beta-Antagonists | 2 | 2019 | 323 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2189 | 0.060 |
Why?
| | Equipment Design | 2 | 2018 | 522 | 0.060 |
Why?
| | Shock | 2 | 2004 | 98 | 0.060 |
Why?
| | Polymerase Chain Reaction | 1 | 2008 | 1062 | 0.060 |
Why?
| | Program Evaluation | 2 | 2019 | 898 | 0.060 |
Why?
| | Exercise | 1 | 2016 | 2057 | 0.060 |
Why?
| | Survival Analysis | 2 | 2020 | 1325 | 0.060 |
Why?
| | Lipid Metabolism | 1 | 2008 | 518 | 0.060 |
Why?
| | Health Plan Implementation | 1 | 2025 | 142 | 0.060 |
Why?
| | Ventricular Fibrillation | 1 | 2024 | 60 | 0.050 |
Why?
| | Trypsin | 1 | 2004 | 77 | 0.050 |
Why?
| | Amylases | 1 | 2003 | 17 | 0.050 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2004 | 132 | 0.050 |
Why?
| | Length of Stay | 2 | 2019 | 1215 | 0.050 |
Why?
| | Chymotrypsin | 1 | 2003 | 22 | 0.050 |
Why?
| | Ezetimibe | 1 | 2023 | 24 | 0.050 |
Why?
| | Hypoglycemic Agents | 2 | 2023 | 1291 | 0.050 |
Why?
| | Tissue Distribution | 1 | 2003 | 332 | 0.050 |
Why?
| | Tachycardia, Ventricular | 1 | 2024 | 175 | 0.050 |
Why?
| | Drug Therapy, Combination | 2 | 2016 | 1066 | 0.050 |
Why?
| | Glucagon-Like Peptide 1 | 1 | 2023 | 135 | 0.050 |
Why?
| | Pancreatitis | 1 | 2003 | 134 | 0.050 |
Why?
| | Rats, Wistar | 1 | 2003 | 455 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 660 | 0.050 |
Why?
| | Personnel Turnover | 1 | 2022 | 40 | 0.050 |
Why?
| | Practice Guidelines as Topic | 2 | 2020 | 1587 | 0.050 |
Why?
| | Cell Death | 1 | 2003 | 374 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2024 | 316 | 0.050 |
Why?
| | Reperfusion Injury | 1 | 2004 | 279 | 0.050 |
Why?
| | Cholesterol, LDL | 1 | 2023 | 365 | 0.040 |
Why?
| | Troponin | 1 | 2021 | 50 | 0.040 |
Why?
| | Neutrophils | 2 | 2004 | 1238 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2025 | 546 | 0.040 |
Why?
| | Organizational Culture | 1 | 2022 | 148 | 0.040 |
Why?
| | Disease Progression | 2 | 2019 | 2757 | 0.040 |
Why?
| | Inpatients | 1 | 2025 | 500 | 0.040 |
Why?
| | Systole | 1 | 2021 | 189 | 0.040 |
Why?
| | Cells, Cultured | 1 | 2008 | 4193 | 0.040 |
Why?
| | Free Radical Scavengers | 1 | 2020 | 88 | 0.040 |
Why?
| | Sodium Bicarbonate | 1 | 2020 | 45 | 0.040 |
Why?
| | Genotype | 1 | 2025 | 1916 | 0.040 |
Why?
| | DNA-Binding Proteins | 1 | 2007 | 1502 | 0.040 |
Why?
| | Cytokines | 1 | 2008 | 2085 | 0.040 |
Why?
| | Job Satisfaction | 1 | 2022 | 218 | 0.040 |
Why?
| | Consensus | 1 | 2023 | 683 | 0.040 |
Why?
| | Sodium | 1 | 2020 | 217 | 0.040 |
Why?
| | Hospitals, High-Volume | 1 | 2019 | 44 | 0.040 |
Why?
| | Acetylcysteine | 1 | 2020 | 145 | 0.040 |
Why?
| | Exercise Tolerance | 1 | 2021 | 279 | 0.040 |
Why?
| | Cost Savings | 1 | 2019 | 84 | 0.040 |
Why?
| | Angiotensin Receptor Antagonists | 1 | 2019 | 92 | 0.040 |
Why?
| | Endocrinologists | 1 | 2018 | 13 | 0.040 |
Why?
| | Drug Utilization | 1 | 2019 | 169 | 0.040 |
Why?
| | Retreatment | 1 | 2018 | 72 | 0.040 |
Why?
| | Comparative Effectiveness Research | 1 | 2019 | 152 | 0.040 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 201 | 0.040 |
Why?
| | Hypertension | 2 | 2018 | 1295 | 0.040 |
Why?
| | Singapore | 1 | 2017 | 22 | 0.040 |
Why?
| | Republic of Korea | 1 | 2017 | 37 | 0.040 |
Why?
| | Rats | 2 | 2004 | 5647 | 0.040 |
Why?
| | Transcription Factors | 1 | 2006 | 1719 | 0.030 |
Why?
| | Angina, Unstable | 1 | 2017 | 76 | 0.030 |
Why?
| | Purpura, Thrombotic Thrombocytopenic | 1 | 2017 | 15 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1236 | 0.030 |
Why?
| | New Jersey | 1 | 2016 | 14 | 0.030 |
Why?
| | Michigan | 1 | 2016 | 109 | 0.030 |
Why?
| | Glomerular Filtration Rate | 1 | 2020 | 746 | 0.030 |
Why?
| | Aortography | 1 | 2016 | 52 | 0.030 |
Why?
| | Postoperative Care | 1 | 2017 | 261 | 0.030 |
Why?
| | Platelet Aggregation | 1 | 2016 | 103 | 0.030 |
Why?
| | Drug Prescriptions | 1 | 2017 | 245 | 0.030 |
Why?
| | Glucose | 1 | 2020 | 1020 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2019 | 556 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 849 | 0.030 |
Why?
| | Hirudins | 1 | 2015 | 53 | 0.030 |
Why?
| | Blood Transfusion | 1 | 2017 | 325 | 0.030 |
Why?
| | Blood Coagulation | 1 | 2016 | 255 | 0.030 |
Why?
| | Protective Factors | 1 | 2014 | 93 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2019 | 1050 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2022 | 2426 | 0.030 |
Why?
| | Health Policy | 1 | 2016 | 388 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 672 | 0.020 |
Why?
| | Emergencies | 1 | 2013 | 164 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2014 | 413 | 0.020 |
Why?
| | Recombinant Proteins | 1 | 2015 | 1353 | 0.020 |
Why?
| | Cost-Benefit Analysis | 1 | 2014 | 591 | 0.020 |
Why?
| | Health Care Costs | 1 | 2014 | 398 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 2017 | 570 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2844 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1783 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2022 | 5778 | 0.020 |
Why?
| | Medicare | 1 | 2014 | 773 | 0.020 |
Why?
| | Clofibrate | 1 | 2007 | 3 | 0.020 |
Why?
| | Orphan Nuclear Receptors | 1 | 2007 | 15 | 0.020 |
Why?
| | Hydrocarbons, Fluorinated | 1 | 2007 | 9 | 0.020 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2007 | 17 | 0.020 |
Why?
| | Liver X Receptors | 1 | 2007 | 31 | 0.020 |
Why?
| | Mice | 1 | 2025 | 17787 | 0.020 |
Why?
| | beta-Cyclodextrins | 1 | 2007 | 28 | 0.020 |
Why?
| | Down-Regulation | 1 | 2007 | 657 | 0.010 |
Why?
| | Physicians | 1 | 2013 | 910 | 0.010 |
Why?
| | Telemedicine | 1 | 2013 | 862 | 0.010 |
Why?
| | Mesenteric Arteries | 1 | 2004 | 16 | 0.010 |
Why?
| | Jejunum | 1 | 2004 | 31 | 0.010 |
Why?
| | Interleukin-10 | 1 | 2006 | 302 | 0.010 |
Why?
| | Gelatin | 1 | 2004 | 52 | 0.010 |
Why?
| | Peroxidase | 1 | 2004 | 175 | 0.010 |
Why?
| | Sulfonamides | 1 | 2007 | 513 | 0.010 |
Why?
| | Microscopy, Fluorescence | 1 | 2004 | 402 | 0.010 |
Why?
| | Enzyme Activation | 1 | 2004 | 810 | 0.010 |
Why?
| | Blotting, Western | 1 | 2004 | 1226 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2004 | 2486 | 0.010 |
Why?
|
|
Waldo's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|